このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Outlook Therapeutics マネジメント

マネジメント基準チェック /34

Outlook Therapeutics'の CEO はRuss Trenaryで、 Jul2021年に任命され、の在任期間は 2.92年です。の年間総報酬は$ 1.76Mで、 34.1%給与と65.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.67%を直接所有しており、その価値は$ 1.19M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と5年です。

主要情報

Russ Trenary

最高経営責任者

US$1.8m

報酬総額

CEO給与比率	34.1%
CEO在任期間	2.9yrs
CEOの所有権	0.7%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	5yrs

経営陣の近況

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

CEO報酬分析

Outlook Therapeutics の収益と比較して、Russ Trenary の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$159m
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

報酬と市場: Russの総報酬 ($USD 1.76M ) は、 US市場 ($USD 1.62M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Russの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Russ Trenary (66 yo)

2.9yrs

在職期間

US$1,758,862

報酬

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ralph Thurman	Independent Executive Chairman	6.2yrs	US$242.50k	0.0025% $ 4.5k
C. Trenary	President	2.9yrs	US$1.76m	0.67% $ 1.2m
Lawrence Kenyon	Executive VP	8.8yrs	データなし	0.0040% $ 7.2k
Jeffrey Evanson	Chief Commercial Officer	5.6yrs	US$718.20k	0.17% $ 306.8k
Alicia Tozier	Senior Vice President	2.3yrs	データなし	データなし
Joel Prieve	Senior Vice President of Licensing and M&A	2.3yrs	データなし	データなし
Surendra Sharma	Senior Vice President of Medical Affairs	1.4yrs	データなし	データなし
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	データなし	データなし
Jedd Comiskey	Senior VP - Head of Europe	less than a year	データなし	データなし

2.6yrs

平均在職期間

62yo

平均年齢

経験豊富な経営陣: OTLKの経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Ralph Thurman	Independent Executive Chairman	6.2yrs	US$242.50k	0.0025% $ 4.5k
C. Trenary	President	2.9yrs	US$1.76m	0.67% $ 1.2m
Lawrence Kenyon	Executive VP	5.8yrs	データなし	0.0040% $ 7.2k
Kurt Hilzinger	Independent Director	8.5yrs	US$95.00k	0.10% $ 179.5k
Julia Haller	Independent Director	1.8yrs	US$79.00k	0% $ 0
Julian Gangolli	Independent Non-Employee Director	4.2yrs	US$112.50k	0% $ 0
Arun Pillai	Board Observer	no data	データなし	データなし
Gerd Auffarth	Independent Non-Employee Director	4.2yrs	US$79.00k	0% $ 0
Faisal Sukhtian	Independent Director	6.8yrs	US$113.00k	0.015% $ 25.8k
Yezan Haddadin	Independent Director	6.7yrs	US$110.00k	0.022% $ 38.3k
Andong Huang	Independent Director	4yrs	US$75.00k	0% $ 0

5.0yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: OTLKの取締役会は経験豊富であると考えられます ( 5年の平均在任期間)。

Outlook Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Recent updates

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought US$257k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics: Likely FDA Approval, Possible Buyout

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

マネジメント基準チェック /34